Join
Live feed
·
PRReleasevia Quantisnow
Oric Pharmaceuticals Inc. logo

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ByQuantisnow·Wall Street's wire, on your screen.
ORIC· Oric Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORIC (Oric Pharmaceuticals Inc.) and more on Quantisnow.